Apple Inc.'s stock has struggled to find positive momentum this year, and analysts at Needham & Company don't see major catalysts ahead that can help put shares on a better course.

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.

Adam Turnquist, a technical strategist at LPL Financial, said the recovery in stock-market breadth is a particularly convincing bullish "tell" suggesting that the market's recovery appears to be on ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

A rally in Deutsche Boerse shares illustrates how Europe is bridging a value gap with its Wall Street peers, as fiscal ...

Once the Nasdaq delisting on Form 25 becomes effective, 23andMe intends to file a Form 15 to deregister with the SEC. About 23andMe 23andMe is a genetics-led consumer healthcare and biotechnology ...

Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract ...

The S&P 500 slipped 0.4% on Tuesday, May 20, snapping a six-day winning streak as investors' confidence on trade and ...

Regeneron is buying bankrupt genetic testing firm 23andMe, which helped usher in the era of consumer DNA test kits nearly two ...